<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00929578</url>
  </required_header>
  <id_info>
    <org_study_id>FP-CL2</org_study_id>
    <nct_id>NCT00929578</nct_id>
  </id_info>
  <brief_title>Fluphenazine Hydrochloride for Psoriasis</brief_title>
  <acronym>FP-CL2</acronym>
  <official_title>Ascending-Dose, Double-Blind, Placebo-Controlled, Study of Intralesional Fluphenazine Hydrochloride for Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immune Control</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the safety and biologic activity of intralesional
      injection of fluphenazine in adult subjects with psoriasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, placebo-controlled, bilateral, ascending dose study.

      In vitro, fluphenazine has been shown to suppress growth of proliferating T-lymphocytes.
      Fluphenazine would be expected to also suppress growth of proliferating T-lymphocytes in
      psoriatic plaques.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Target Lesion Scoring Evaluated at Baseline and 4 Weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>Actual change in target lesion score comparing 4 week score with baseline score. Improvement is positive, worsening is negative. Target lesions scores range from 0 (no disease) to 12 (severe disease), and are scored based on the sum of erythema (0-4), induration (0-4) and scale (0-4) scores.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Target Lesion Visual Analog Scale (VAS) Score for Pruritus Evaluated at Baseline and 4 Weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>Visual Analog Scale (VAS) score for pruritus. Subjective measurement of pruritus on an analog scale with a single mark denoting self-perceived pruritus: Minimum 0mm for no itch, Maximum 100mm for worst itch imaginable. Scores are measured in millimeters. This secondary outcome is a percentage improvement from baseline score for pruritus. Improvement is negative, worsening is positive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome Measures</measure>
    <time_frame>8 weeks</time_frame>
    <description>adverse events will be recorded and monitored. Adverse events will be noted in a separate chart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluphenazine Serum Levels Measured at Baseline, 2 Hours Post Dose and 1 Week Post Dose.</measure>
    <time_frame>1 week</time_frame>
    <description>Number of participants with fluphenazine serum levels &gt; 0.200ng/ml, at baseline, 2 hours post dose and 1 week post dose.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The sterile placebo: Bacteriostatic Sodium Chloride for Injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluphenazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This will be an ascending dose study with the first cohort of 5 subjects dosed at 100 µg/mL, followed by cohorts at 500 and 2500 µg/mL. Dosing will be on Days 0, 7 and 14 and will consist of 5, or 10, 100 µL injections into the psoriatic lesion. The number of injections will depend on the lesion size. As this is a vehicle controlled study, subjects will receive intralesional injections of both drug and placebo, each into a separate target plaque, in a randomized fashion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluphenazine</intervention_name>
    <description>Intralesional injection of Fluphenazine</description>
    <arm_group_label>Fluphenazine</arm_group_label>
    <other_name>FP-CL2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intralesional injection of placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Bacteriostatic Sodium Chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults 18 to 65 years of age with psoriasis, in general good health as determined by
             the Principal Investigator based upon the results of medical history, laboratory
             profile, and physical examination

          -  Must have symmetric target lesions 2-4 cm in diameter on each side of the body (e.g.,
             thighs) with baseline Target Lesion Score (TLS) of 6 or higher (scale of 0-12) for
             each target

          -  Women are eligible to participate in the study if they meet one of the following
             criteria:

               -  Women who are postmenopausal (for at least one year), sterile, or hysterectomized

               -  Women of childbearing potential must undergo monthly pregnancy testing during the
                  study and agree to use two of the following methods of contraception throughout
                  the study and for 60 days after the last dose of study drug:

                    -  Oral contraceptives

                    -  Transdermal contraceptives

                    -  Injectable or implantable methods

                    -  Intrauterine devices

                    -  Barrier methods (diaphragm with spermicide, condom with spermicide)

        (Abstinence and Tubal Ligation are also considered a form of Birth control.)

        Exclusion Criteria:

          -  Patient is not asymptomatic and has major ailments on screening exam.

          -  Infliximab (Remicade®) or alefacept (Amevive®) within the past 6 months (24 weeks)

          -  Etanercept (Enbrel®), efalizumab (Raptiva™), adalimumab (Humira®) or other tumor
             necrosis factor (TNF)-alpha inhibitor within the past 3 months (12 weeks)

          -  Other systemic psoriasis therapies (e.g., methotrexate, cyclosporine, acitretin) or
             oral psoralen with ultraviolet A (PUVA) within the past 4 weeks

          -  ultraviolet B (UVB) or topical therapy (other than over-the-counter (OTC) moisturizers
             and shampoos) within the past 2 weeks (including topical corticosteroids, vitamin A
             and D analogues) with the exception of betamethasone valerate lotion (0.01%) for
             treatment of scalp lesions, and triamcinolone cream (0.1%) for lesions at least 3
             inches away from the target lesions

          -  Receipt of an investigation agent within the past 4 weeks

          -  Systemic corticosteroid therapy

          -  Inability to understand consent or comply with protocol (patients will be asked if
             they understand or have any questions)

          -  Pregnancy, lactation, or unwillingness to use adequate birth control during the study

          -  Impaired hepatic function

          -  Known HIV/AIDS, hepatitis B/C

          -  Blood dyscrasia

          -  Epilepsy

          -  Tardive dyskinesia

          -  Excessive alcohol consumption (drinking more than two drinks per day on average for
             men or more than one drink per day on average for women)

          -  Use of phenothiazine antipsychotics or anticholinergics

          -  Current use of selective serotonin reuptake inhibitor (SSRI), tricyclic, or
             norepinephrine reuptake inhibitor antidepressants or use within 6 weeks of beginning
             the study

          -  Concurrent use of anti-seizure drugs, with the exception of gabapentin for treatment
             of neuropathy

          -  Known allergy to fluphenazine or other phenothiazines, sesame oil or sesame seeds

          -  Known allergy to parabens, para-aminobenzoate (PABA) or benzyl alcohol

          -  Clinically significant and uncontrolled cardiovascular disease

          -  corrected QT interval (QTc) &gt; 450 msec, or evidence of a clinically significant
             dysrhythmia on ECG

          -  Operator of heavy machinery

          -  Pheochromocytoma

          -  Clinically significant mitral valve disease

          -  History of breast cancer

          -  History of seizure disorder

          -  Occupational exposure to organophosphate insecticides

          -  Parkinson's disease and other related movement disorders

          -  Screening Lab abnormalities including:

               -  Serum Asparate transaminase (AST) or Alanine transaminase (ALT) &gt; 2.5 upper
                  limits of normal

               -  Creatinine ≥ 1.6 mg/dL

               -  Bilirubin ≥ 1.5 mg/dL

               -  White blood cell (WBC) count &lt; 3 x 10^9 /L

               -  Platelets &lt; 100 x 10^9/L

               -  Hemoglobin &lt; 10 g/dL in females or &lt; 12g/dL in males

               -  Glucose ≥ 200 mg/dL

               -  Fasting blood sugar ≥ 126 mg/dL

          -  Concurrent use of drugs listed in Appendix E of protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alice B. Gottlieb, M.D., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center, Department of Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tufts Medical Center, Department of Dermatology</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Wood Johnson Medical School, Psoriasis Center of Excellence</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.tuftsmedicalcenter.org/OurServices/Dermatology/default?Page=5</url>
    <description>Tufts Medical Center, Department of Dermatology, Research</description>
  </link>
  <reference>
    <citation>Gupta MA, Guptat AK. The use of antidepressant drugs in dermatology. J Eur Acad Dermatol Venereol. 2001 Nov;15(6):512-8. Review.</citation>
    <PMID>11843209</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2009</study_first_submitted>
  <study_first_submitted_qc>June 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2009</study_first_posted>
  <results_first_submitted>August 13, 2012</results_first_submitted>
  <results_first_submitted_qc>June 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 2, 2016</results_first_posted>
  <last_update_submitted>March 2, 2017</last_update_submitted>
  <last_update_submitted_qc>March 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>T-lymphocytes</keyword>
  <keyword>Fluphenazine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluphenazine</mesh_term>
    <mesh_term>Fluphenazine depot</mesh_term>
    <mesh_term>Fluphenazine enanthate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment from a dermatology clinic of a tertiary care medical center. Recruitment dates from Oct 2008 to Sep 2010.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>The sterile placebo: Bacteriostatic Sodium Chloride for Injection. Same subject will also receive dose in other arm of fluphenazine. This will be an ascending dose study with the first cohort of 5 subjects dosed at 100 µg/mL, followed by cohorts at 500 and 2500 µg/mL. Dosing will be on Days 0, 7 and 14 and will consist of 5, or 10, 100 µL injections into the psoriatic lesion. The number of injections will depend on the lesion size. As this is a vehicle controlled study, subjects will receive intralesional injections of both drug and placebo, each into a separate target plaque, in a randomized fashion.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants - Fluphenazine</title>
          <description>This will be an ascending dose study with the first cohort of 5 subjects dosed at 100 µg/mL, followed by cohorts at 500 and 2500 µg/mL. Dosing will be on Days 0, 7 and 14 and will consist of 5, or 10, 100 µL injections into the psoriatic lesion. The number of injections will depend on the lesion size. As this is a vehicle controlled study, subjects will receive intralesional injections of both drug and placebo, each into a separate target plaque, in a randomized fashion.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.5" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Target Lesion Scoring Evaluated at Baseline and 4 Weeks</title>
        <description>Actual change in target lesion score comparing 4 week score with baseline score. Improvement is positive, worsening is negative. Target lesions scores range from 0 (no disease) to 12 (severe disease), and are scored based on the sum of erythema (0-4), induration (0-4) and scale (0-4) scores.</description>
        <time_frame>4 weeks</time_frame>
        <population>All participants who successfully were enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>The sterile placebo: Bacteriostatic Sodium Chloride for Injection.</description>
          </group>
          <group group_id="O2">
            <title>Fluphenazine</title>
            <description>This will be an ascending dose study with the first cohort of 5 subjects dosed at 100 µg/mL, followed by cohorts at 500 and 2500 µg/mL. Dosing will be on Days 0, 7 and 14 and will consist of 5, or 10, 100 µL injections into the psoriatic lesion. The number of injections will depend on the lesion size. As this is a vehicle controlled study, subjects will receive intralesional injections of both drug and placebo, each into a separate target plaque, in a randomized fashion.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Target Lesion Scoring Evaluated at Baseline and 4 Weeks</title>
          <description>Actual change in target lesion score comparing 4 week score with baseline score. Improvement is positive, worsening is negative. Target lesions scores range from 0 (no disease) to 12 (severe disease), and are scored based on the sum of erythema (0-4), induration (0-4) and scale (0-4) scores.</description>
          <population>All participants who successfully were enrolled.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="1.5"/>
                    <measurement group_id="O2" value="-1.4" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Target Lesion Visual Analog Scale (VAS) Score for Pruritus Evaluated at Baseline and 4 Weeks</title>
        <description>Visual Analog Scale (VAS) score for pruritus. Subjective measurement of pruritus on an analog scale with a single mark denoting self-perceived pruritus: Minimum 0mm for no itch, Maximum 100mm for worst itch imaginable. Scores are measured in millimeters. This secondary outcome is a percentage improvement from baseline score for pruritus. Improvement is negative, worsening is positive.</description>
        <time_frame>4 weeks</time_frame>
        <population>Participants who completed entire trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>The sterile placebo: Bacteriostatic Sodium Chloride for Injection.</description>
          </group>
          <group group_id="O2">
            <title>Fluphenazine</title>
            <description>This will be an ascending dose study with the first cohort of 5 subjects dosed at 100 µg/mL, followed by cohorts at 500 and 2500 µg/mL. Dosing will be on Days 0, 7 and 14 and will consist of 5, or 10, 100 µL injections into the psoriatic lesion. The number of injections will depend on the lesion size. As this is a vehicle controlled study, subjects will receive intralesional injections of both drug and placebo, each into a separate target plaque, in a randomized fashion.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Target Lesion Visual Analog Scale (VAS) Score for Pruritus Evaluated at Baseline and 4 Weeks</title>
          <description>Visual Analog Scale (VAS) score for pruritus. Subjective measurement of pruritus on an analog scale with a single mark denoting self-perceived pruritus: Minimum 0mm for no itch, Maximum 100mm for worst itch imaginable. Scores are measured in millimeters. This secondary outcome is a percentage improvement from baseline score for pruritus. Improvement is negative, worsening is positive.</description>
          <population>Participants who completed entire trial.</population>
          <units>percentage of baseline pruritus</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" spread="15.0"/>
                    <measurement group_id="O2" value="-2.16" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome Measures</title>
        <description>adverse events will be recorded and monitored. Adverse events will be noted in a separate chart.</description>
        <time_frame>8 weeks</time_frame>
        <population>All participants who completed enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
            <description>Participants who experienced at least one adverse event.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome Measures</title>
          <description>adverse events will be recorded and monitored. Adverse events will be noted in a separate chart.</description>
          <population>All participants who completed enrollment.</population>
          <units>All Study Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fluphenazine Serum Levels Measured at Baseline, 2 Hours Post Dose and 1 Week Post Dose.</title>
        <description>Number of participants with fluphenazine serum levels &gt; 0.200ng/ml, at baseline, 2 hours post dose and 1 week post dose.</description>
        <time_frame>1 week</time_frame>
        <population>All participants who were enrolled and completed baseline and week 1 were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Number of participants with fluphenazine serum levels &gt; 0.200ng/ml at baseline</description>
          </group>
          <group group_id="O2">
            <title>2 Hours Post Dose</title>
            <description>Number of participants with fluphenazine serum levels &gt; 0.200ng/ml, 2 hours after administration</description>
          </group>
          <group group_id="O3">
            <title>1 Week Post Dose</title>
            <description>Participants with fluphenazine serum levels &gt; 0.200ng/ml</description>
          </group>
        </group_list>
        <measure>
          <title>Fluphenazine Serum Levels Measured at Baseline, 2 Hours Post Dose and 1 Week Post Dose.</title>
          <description>Number of participants with fluphenazine serum levels &gt; 0.200ng/ml, at baseline, 2 hours post dose and 1 week post dose.</description>
          <population>All participants who were enrolled and completed baseline and week 1 were included.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year, 10 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Study Participants</title>
          <description>This will be an ascending dose study with the first cohort of 5 subjects dosed at 100 µg/mL, followed by cohorts at 500 and 2500 µg/mL. Dosing will be on Days 0, 7 and 14 and will consist of 5, or 10, 100 µL injections into the psoriatic lesion. The number of injections will depend on the lesion size. As this is a vehicle controlled study, subjects will receive intralesional injections of both drug and placebo, each into a separate target plaque, in a randomized fashion. All participants received medication, as the study was a split study, and subjects received placebo on one side and injection of fluphenazine on other side</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Eyes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Difficulty Sleeping</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Unusual dreams</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abrasion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sprained Medial Collateral Ligament</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Ankle Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Nightmares</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <description>Self limited Upper Respiratory Infection</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Xerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nighttime Sweats</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Bruise, Upper left arm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Blisters</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alice Gottlieb, MD PhD</name_or_title>
      <organization>Tufts Medical Center</organization>
      <phone>617-636-7462</phone>
      <email>agottlieb@tuftsmedicalcenter.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

